Larimar Therapeutics reported a net loss of $31.1 million for the third quarter of 2026, an improvement from the $47.7 million loss in the prior year period, primarily driven by a significant decrease in research and development expenses. The company strengthened its balance sheet through equity issuances, ending September 30, 2026, with $128.7 million in cash, cash equivalents, and marketable securities.
Larimar Therapeutics reported third quarter 2026 financial results and announced the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich’s ataxia. The company ended the quarter with $128.7 million in cash, providing a projected runway into late Q2 2027 as it prepares for a potential U.S. launch in Q3 2027.
“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community. The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”
Carole Ben-Maimon, M.D., Chief Executive Officer
“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”
Larimar Therapeutics Director Thomas Edward Hamilton Buys $187K of Stock
Thomas Edward Hamilton, Director, bought 70,000 shares of Larimar Therapeutics, Inc. at $2.67 a share, worth $187K in total on Nov 12, 2026. Shares held after the trade: 70,000.
Larimar Therapeutics President and CEO Carole Ben-maimon Buys $50K of Stock
Carole Ben-maimon, President and CEO, bought 18,050 shares of Larimar Therapeutics, Inc. at $2.77 a share, worth $50K in total on Nov 11, 2026. Shares held after the trade: 386,326 (+4.9%).
Larimar Therapeutics Director Frank E. Thomas Buys $21.8K of Stock
Frank E. Thomas, Director, bought 8,000 shares of Larimar Therapeutics, Inc. at $2.73 a share, worth $21.8K in total on Nov 11, 2026. Shares held after the trade: 15,000 (+114.3%).
Larimar Therapeutics President and COO John B. Harlow Jr. Buys $49.9K of Stock
John B. Harlow Jr., President and COO, bought 17,800 shares of Larimar Therapeutics, Inc. at $2.80 a share, worth $49.9K in total on Nov 11, 2026. Shares held after the trade: 67,800 (+35.6%).
Larimar Therapeutics CFO Michael Celano Buys $50K of Stock
Michael Celano, CFO, bought 18,460 shares of Larimar Therapeutics, Inc. at $2.71 a share, worth $50K in total on Nov 11, 2026. Shares held after the trade: 234,245 (+8.6%).
Larimar Therapeutics Chief Development Officer Gopi Shankar Buys $13.5K of Stock
Gopi Shankar, Chief Development Officer, bought 5,000 shares of Larimar Therapeutics, Inc. at $2.71 a share, worth $13.5K in total on Nov 11, 2026. Shares held after the trade: 81,443 (+6.5%).